Transcatheter aortic valve implantation: Current status and future perspectives

Table 2 Clinical outcomes across the most recent published studies

	Year published	Patients	Valve	Access	Procedural success (%)	30-d mortality (%)	1-yr mortality (%)
PARTNER EU[55]	2010	61	ES	TF	91	8.1	21.3
SOURCE Registry[56]	2010	463	ES	TF	95.2	6.3	-
PARTNER cohort B[11]	2010	179	ES	TF	-	5	30.7
Rodés-Cabau et al[24]	2010	168	ES	TF	90.5	9.5	25
PARTNER cohort A[12]	2011	244	ES	TF	-	3.3	22.2
PARTNER EU[55]	2010	69	ES	TA	91	18.8	51.7
SOURCE Registry[56]	2010	575	ES	TA	92.7	10.3	-
Rodés-Cabau et al[24]1	2010	177	ES	TA	96.1	11.3	23
Wong et al[45]1	2010	60	ES	TA	98.3	18.3	-
PARTNER cohort A[12]	2011	104	ES	TA	-	3.8	29
Grube et al[43]	2008	1022	CS	TF	91.2	10.8	-
Piazza et al[57]	2008	646	CS	TF	97.2	8	-
Avanzas et al[58]	2010	108	CS	103 TF/5 TS	98.1	7.4	17.7
Tamburino et al[27]	2011	663	CS	599 TF/64 TS	98	5.4	15

¹Dr. Wong and Dr. Rodés-Cabau are from the same centre, probably patients overlapped in these two studies;

²Results referred to the third generation Corevalve ReValving System (CS) device only. ES: Edwards SAPIEN; TF: Transfemoral; TA: Transapical; TS: Trans-subclavian.